Summary
This article discusses the results from the Assessment of Weekly Administration of LY2189265 in Diabetes-4 trial [AWARD-4; NCT01191268], which indicate that dulaglutide, in combination with insulin lispro, is an effective and safe option for treatment intensification in type 2 diabetes patients who are inadequately controlled on 1 or 2 doses of insulin.
- Diabetes & Endocrinology Clinical Trials
- Hyperglycemia/Hypoglycemia
- Diabetes Mellitus
- Diabetes & Endocrinology Clinical Trials
- Hyperglycemia/Hypoglycemia
- Diabetes Mellitus
- Endocrinology
- Diabetes & Metabolic Syndrome
- © 2014 MD Conference Express®
Tools
Dulaglutide Reduces HbA1c More Than Glargine When Used in Combination with Prandial Insulin
Permalink:
